ign002
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02519270)
Timeline
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ign002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02847949 | Phase 2 | Aug 1, 2016 | ImmunGene Inc., The Leukemia and Lymphoma Society, Valor Biotherapeutics |
| NCT02519270 | Phase 1 | Dec 1, 2015 | ImmunGene Inc., The Leukemia and Lymphoma Society |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmunGene Inc. | For profit | 2 | 2 | 2 | 2015 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 2 | 0 | 2 | 2015 |
| Valor Biotherapeutics | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1